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Hepatic steatosis, the accumulation of lipids in
the liver, is widely believed to result in insulin
resistance. To test the causal relationship be-
tween hepatic steatosis and insulin resistance,
we generated mice that overexpress acyl-
CoA:diacylglycerol acyltransferase 2 (DGAT2),
which catalyzes the final step of triacylglycerol
(TG) biosynthesis, in the liver (Liv-DGAT2
mice). Liv-DGAT2mice developed hepatic stea-
tosis, with increased amounts of TG, diacylgly-
cerol, ceramides, and unsaturated long-chain
fatty acyl-CoAs in the liver. However, they had
no abnormalities in plasma glucose and insulin
levels, glucose and insulin tolerance, rates of
glucose infusion and hepatic glucose produc-
tion during hyperinsulinemic-euglycemic clamp
studies, or activities of insulin-stimulated sig-
naling proteins in the liver. DGAT1 overexpres-
sion in the liver also failed to induce glucose
or insulin intolerance. Our results indicate that
DGAT-mediated lipid accumulation in the liver
is insufficient to cause insulin resistance and
show that hepatic steatosis can occur indepen-
dently of insulin resistance.
INTRODUCTION
Obesity is often accompanied by the excessive accumu-
lation of lipids in nonadipose tissues (Friedman, 2002;
Schaffer, 2003; Unger, 2002). One such process, hepaticsteatosis, the accumulation of lipids in the liver, is increas-
ing in prevalence, with current estimates ranging from
14% to 34% of the general population (Kim et al., 2004;
Seppala-Lindroos et al., 2002; Szczepaniak et al., 2005;
Wieckowska and Feldstein, 2005). Hepatic steatosis is
part of the spectrum of nonalcoholic fatty liver diseases,
which include the serious consequences of steatohepati-
tis and cirrhosis (Browning and Horton, 2004). Because
hepatic steatosis is an increasing concern for public
health, a better understanding of its pathophysiology
and its consequences is of great importance.
Hepatic steatosis is strongly associated with insulin
resistance. Numerous studies in humans and animals
have shown that insulin-resistant states are often accom-
panied by hepatic steatosis (Angulo and Lindor, 2001;
Marchesini et al., 1999, 2005; Petersen and Shulman,
2006; Seppala-Lindroos et al., 2002; Yki-Jarvinen, 2005).
For example, leptin-deficient ob/ob mice, lipodystrophic
mice, and mice fed a high-fat diet all develop severe insu-
lin resistance and hepatic steatosis (Browning and Horton,
2004; den Boer et al., 2004; Halaas et al., 1995; Koteish
and Mae Diehl, 2002; Shimomura et al., 1999a, 1999b).
However, the causal relationship between hepatic
steatosis and insulin resistance is uncertain. On the one
hand, it seems clear that systemic insulin resistance may
lead to steatosis. Insulin resistance is often accompanied
by hyperinsulinemia, which can activate hepatic signaling
pathways and sterol regulatory element binding protein 1c
(SREBP-1c), which in turn activates the transcription of
genes involved in fatty acid biosynthesis (Farese et al.,
2005a; Matsumoto et al., 2003; Shimomura et al., 2000).
On the other hand, whether hepatic steatosis is sufficient
to cause hepatic insulin resistance is less clear. Acute
intravenous infusions of lipids or chronic high-fat feeding
can result in hepatic steatosis that is accompanied byCell Metabolism 6, 69–78, July 2007 ª2007 Elsevier Inc. 69
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2004; Gauthier et al., 2003; Winzell and Ahren, 2004).
However, models of lipid administration are complex
and may be accompanied by alterations not restricted to
the liver, making it difficult to determine the contribution
of steatosis to insulin resistance.
To directly test the hypothesis that hepatic steatosis
leads to insulin resistance, we studied transgenic mice
that overexpress human DGAT enzymes, which catalyze
the final step of triacylglycerol (TG) biosynthesis (Buhman
et al., 2001), in the liver. We focused on mice overexpress-
ing DGAT2 (Liv-DGAT2mice), the more potent (Stone et al.,
2004) and specific (Yen et al., 2005) DGAT for increasing TG
synthesis. We analyzed the phenotype of Liv-DGAT2mice,
focusing on hepatic lipid accumulation and the effects of
steatosis on hepatic insulin signaling and whole-body
glucose metabolism. To further test the hypothesis, we
also analyzed glucose metabolism in a line of Liv-DGAT2
mice with higher expression levels and in transgenic mice
that overexpress DGAT1 in the liver.
RESULTS
Generation of Mice Overexpressing Human DGAT2
in the Liver
Liv-DGAT2 mice were generated with a DNA construct
containing the hepatic promoter/enhancer sequences
Figure 1. Generation of Liv-DGAT2 Mice
(A) DNA construct for generating Liv-DGAT1 and Liv-DGAT2 mice.
Expression of the humanDGAT cDNA is driven by theAPOE promoter/
enhancer sequences.
(B) DGAT2 mRNA levels in tissues of Liv-DGAT2 mice. Total (mouse
and human) DGAT2 mRNA levels were measured by real-time PCR.
Tissues were from 12- to 14-week-old male mice (n = 6–9) on an ad
libitum chow diet. *p < 0.001 versus WT. In this and all other figures,
error bars represent ±SEM.
(C) Increased DGAT2 protein levels in livers of Liv-DGAT2 mice.
Homogenate samples (100 mg) were analyzed by SDS-PAGE and
immunoblotting.70 Cell Metabolism 6, 69–78, July 2007 ª2007 Elsevier Inc.from the human apolipoprotein E (APOE) gene (Figure 1A).
Of five founder lines, we analyzed one with lower expres-
sion levels (Liv-DGAT2-low) and one with higher levels (Liv-
DGAT2-high) (2.1- and 3.5-fold increase in total hepatic
DGAT2 mRNA) (Figure 1B). DGAT2 mRNA expression
was increased only in the liver in Liv-DGAT2-low mice but
was also increased in the kidney and brain of Liv-DGAT2-
high mice. (This APOE promoter/enhancer construct has
been reported to drive expression in the kidney [Simonet
et al., 1993].) DGAT2 mRNA expression was almost unde-
tectable and was not increased in peritoneal macrophages
of Liv-DGAT2-low mice (data not shown). The increase in
DGAT2 mRNA levels in the livers of transgenic mice corre-
lated with increased amounts of DGAT2 protein (Figure 1C).
Hepatic Steatosis in Liv-DGAT2 Mice
Both Liv-DGAT2-low and Liv-DGAT2-high mice devel-
oped hepatic steatosis, which was evident by proportional
increases in the size and paleness of their livers (Figure 2A).
Figure 2. Hepatic Steatosis in Liv-DGAT2 Mice
(A) Livers from 13-week-old male mice.
(B) Levels of triacylglycerol (TG), diacylglycerol (DG), and ceramides in
tissues of Liv-DGAT2 mice. Lipid content of tissues was measured in
12- to 15-week-old male mice (n = 6–10) on an ad libitum chow diet.
*p < 0.05, **p < 0.001 versus WT.
(C) Levels of fatty acyl-CoAs in livers of Liv-DGAT2 and Liv-DGAT1
mice. Fatty acyl-CoAs were measured in livers of 12- to 15-week-old
male mice (n = 7–10) on an ad libitum chow diet. *p < 0.05, **p <
0.01, ***p < 0.001 versus WT.
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Parameter Wild-Type Liv-DGAT2-Low Liv-DGAT2-High Liv-DGAT1
Fat mass (%) 4.58 ± 0.43 4.66 ± 0.32 5.06 ± 0.32 3.51 ± 0.19
Lean mass (%) 20.9 ± 0.41 20.17 ± 0.37 18.65 ± 0.40 20.2 ± 0.64
Food intake (g/day) 3.71 ± 0.22 4.18 ± 0.28 ND ND
FFA (mmol/l) 0.96 ± 0.04 0.80 ± 0.06* 0.80 ± 0.07 0.92 ± 0.06
Triacylglycerol (mg/dl) 48.8 ± 2.0 15.5 ± 1.2** 13.0 ± 0.7** 10.2 ± 1.1**
b-hydroxybutyrate (mM) 0.257 ± 0.08 0.254 ± 0.06 0.233 ± 0.04 0.161 ± 0.01*
Glucose (mg/dl)
after 16 hr fast 90.1 ± 3.4 87.0 ± 5.5 84.1 ± 2.5 104 ± 6.3
after 6 hr fast 181 ± 4.8 194 ± 5.5 170 ± 13.2 156 ± 4.7*
Insulin (6 hr fast; ng/ml) 0.41 ± 0.04 0.35 ± 0.04 0.45 ± 0.06 0.59 ± 0.07
ALT (U/l) 42 ± 2.1 63 ± 12* 124 ± 25** ND
AST (U/l) 84.2 ± 4.3 104 ± 12* 178 ± 30** ND
MCP-1 (pg/ml) 148 ± 20 ND 175 ± 18 ND
tPAI-1 (ng/ml) 2.90 ± 0.23 ND 3.46 ± 0.51 ND
Leptin (ng/ml) 5.28 ± 0.40 ND 6.22 ± 1.46 ND
Resistin (ng/ml) 1.96 ± 0.10 ND 2.18 ± 0.29 ND
Adiponectin (mg/ml) 10.5 ± 0.36 ND 10.3 ± 0.73 ND
FFA, free fatty acid; ALT, alanine transaminase; AST, aspartate aminotransferase; MCP-1, monocyte chemoattractant protein 1;
tPAI-1, tissue plasminogen activator inhibitor 1; ND, not determined. n = 5–40 mice per group. *p < 0.05, **p < 0.001 versus WT.The ratio of liver weight to body weight was higher in Liv-
DGAT2 mice (0.050 ± 0.001 for Liv-DGAT2-low and
0.067 ± 0.002 for Liv-DGAT2-high versus 0.047 ± 0.001
for wild-type [WT] mice; n = 10–20, p < 0.005). The hepatic
TG content was increased 5-fold in Liv-DGAT2-low mice
and17-fold in Liv-DGAT2-high mice (Figure 2B). TG con-
tents in skeletal muscle were similar in WT and Liv-DGAT2
mice. The tissue content of diacylglycerol (DG) and ceram-
ides, two lipids implicated in impaired insulin signaling
(Kim et al., 2001; Neschen et al., 2005; Schaffer, 2003;
Unger, 2002), was increased proportionally in the livers of
Liv-DGAT2-low and Liv-DGAT2-high mice but not in the
skeletal muscle. Similarly, the content of unsaturated
long-chain fatty acyl-CoAs (C16:1, C18:1, and C18:2)
was increased in the livers of both groups (Figure 2C).
The content of saturated long-chain fatty acyl-CoAs
(C16:0 and C18:0) and arachidonyl-CoA (C20:4) was not
increased.
The overexpression of DGAT2 in the liver had no effect
on body composition or food intake (Table 1). However,
plasma transaminase levels were slightly higher in Liv-
DGAT2-low mice and 2- to 3-fold higher in Liv-DGAT2-
high mice (Table 1). Plasma levels of adipokines (leptin,
resistin, and adiponectin) and inflammatory markers
(monocyte chemoattractant protein 1 and tissue plasmin-
ogen activator inhibitor 1) were similar in WT and Liv-
DGAT2-high mice (Table 1). Plasma TG levels of fasted
mice were decreased by more than 65% in both Liv-
DGAT2-low and Liv-DGAT2-high mice (Table 1); plasma
fatty acid levels were also slightly decreased. Levels ofb-hydroxybutyrate were similar in WT and Liv-DGAT2
mice, suggesting similar rates of hepatic fatty acid oxida-
tion. TG secretion from the liver, measured after injection
of tyloxapol (an inhibitor of very low-density lipoprotein
catabolism), was similar in WT and Liv-DGAT2-low mice
(data not shown).
Next, we examined the hepatic expression of several
genes involved in fatty acid synthesis and oxidation in
Liv-DGAT2 mice. mRNA levels of three enzymes involved
in fatty acid synthesis (SREBP-1c, fatty acid synthase
[FAS], and stearoyl-CoA desaturase 1 [SCD-1]) were
increased in both Liv-DGAT2-low and Liv-DGAT2-high
mice (Figure 3). The mRNA levels of peroxisome prolifera-
tor-activated receptor a (PPARa), a transcription factor
that promotes fatty acid oxidation, trended higher in Liv-
DGAT2 mice, although the differences were not signifi-
cant. However, mRNA levels of acyl-CoA oxidase (ACOX)
and medium-chain acyl-CoA dehydrogenase (MCAD),
two enzymes that are PPARa targets, were higher in Liv-
DGAT2-high mice. mRNA levels of carnitine palmitoyl-
transferase (CPT1), a protein involved in translocating fatty
acids into the mitochondria for oxidation, and cytochrome
c (Cyt c) were higher in Liv-DGAT2-high mice.
Liv-DGAT2-Low Mice Are Not Insulin Resistant
Because the Liv-DGAT2-low mice had steatosis and over-
expressed DGAT2 only in the liver, we chose this line to
comprehensively investigate glucose and insulin metabo-
lism. Blood glucose and plasma insulin levels of fasted
Liv-DGAT2-low mice were similar to those of WT miceCell Metabolism 6, 69–78, July 2007 ª2007 Elsevier Inc. 71
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or insulin tolerance (Figures 4A and 4B). In hyperinsuline-
mic-euglycemic clamp studies, WT and Liv-DGAT2-low
mice had similar rates of glucose infusion (GIR; Figure 4C),
hepatic glucose production (HGP; Figure 4D), and insulin-
stimulated glucose disposal (IS-GDR; Figure 4E), which
reflects insulin sensitivity in peripheral tissues, further
demonstrating that Liv-DGAT2-low mice are not insulin re-
sistant. A submaximal insulin infusion rate (2 mU/kg/min)
was chosen to allow the detection of subtle defects in he-
patic insulin action that might not be detected with supra-
physiologic insulin doses; this infusion rate was sufficient
to induce phosphorylation of serine 473 of PKB/Akt in the
liver (Figure 4F). Consistent with the results from the clamp
studies, liver mRNA levels of phosphoenolpyruvate car-
boxykinase (PEPCK) and glucose-6-phosphatase (G6P),
two key enzymes in gluconeogenesis, were not increased
in Liv-DGAT2-low mice (Figure 3).
We also examined signaling in response to insulin
administered intraperitoneally in the livers of Liv-DGAT2-
low and WT mice. The activities of phosphatidylinositol
3-kinase (PI3K) (Figure 4G) and protein kinase C (PKC)
l/z (Figure 4H), a sensitive marker of insulin signaling
(Farese et al., 2005b), were similar in liver homogenates,
as were serine 473 phosphorylation levels of PKB/Akt
(Figure 4I).
Figure 3. Hepatic Expression of Lipogenic, Oxidative, and
Gluconeogenic Genes in Liv-DGAT2-Low and Liv-DGAT2-
High Mice
mRNA levels were quantified by real-time PCR in 12- to 14-week-old
male mice (n = 6 per genotype) on an ad libitum chow diet. *p <
0.05, **p < 0.01, ***p < 0.001 versus WT.72 Cell Metabolism 6, 69–78, July 2007 ª2007 Elsevier Inc.Glucose tolerance in older (age 7 and 11 months) Liv-
DGAT2-low mice was similar to that in WT mice (data
not shown). Liv-DGAT2-low mice were also fed a high-
fat diet for 16 weeks to exacerbate the steatosis and fur-
ther challenge liver function. At the end of the dietary chal-
lenge, total DGAT2 mRNA levels and TG content in the
liver were similar in Liv-DGAT2-low and WT mice (data
not shown). With the similar levels of DGAT2 expression
and steatosis after the high-fat diet, we did not expect dif-
ferences in glucose metabolism, and, indeed, glucose tol-
erance and insulin tolerance were similarly impaired in WT
and Liv-DGAT2-low mice fed the high-fat diet (data not
shown).
Normal Glucose and Insulin Tolerance
in Liv-DGAT2-High Mice
We also examined glucose metabolism in Liv-DGAT2-
high mice, which exhibited considerably more steatosis
than Liv-DGAT2-low mice. Fasting blood glucose and
plasma insulin levels were similar in Liv-DGAT2-high
mice and WT mice (Table 1), as were glucose and insulin
tolerance (see Figures S1A and S1B in the Supplemental
Data available with this article online). Interestingly, mRNA
levels of PEPCK, but not glucose-6-phosphatase, were
increased in livers of Liv-DGAT2-high mice (Figure 3).
Normal Glucose Tolerance in Liv-DGAT1 Mice
To further test the relationship between hepatic steatosis
and glucose metabolism, we generated mice that overex-
press human DGAT1 specifically in the liver. Dgat1 is ex-
pressed normally at relatively low levels in murine liver
(Cases et al., 1998), and the levels of total DGAT1 mRNA
in the liver were more than 90-fold higher in Liv-DGAT1
mice than in WT mice (Figure 5A). DGAT1 mRNA levels
in skeletal muscle were similar to those of WT mice. As
in Liv-DGAT2-low mice, the mRNA levels of fatty acid
synthase and stearoyl-CoA desaturase 1 were increased
in livers of Liv-DGAT1 mice. The increase in hepatic
DGAT1 expression was accompanied by a 3-fold
increase in TG content, a 3.5-fold increase in ceramide
levels (Figure 5B), and higher levels of C18:1 and
C18:2 fatty acyl-CoAs in the liver (Figure 2C). Hepatic
DG content was similar in WT and Liv-DGAT1 mice
(Figure 5B). Body composition was similar in WT and
Liv-DGAT1 mice (Table 1). Plasma levels of glucose and
insulin were not increased in Liv-DGAT1 mice (Table 1),
and Liv-DGAT1 mice had normal glucose (Figure 5C)
and insulin tolerance (Figure 5D).
Similar Markers of Inflammation in the Livers
of Liv-DGAT Mice
Hepatic steatosis can be accompanied by inflammation
and endoplasmic reticulum (ER) stress (Arkan et al.,
2005; Day, 2006; Feldstein et al., 2004; Ozcan et al.,
2004), factors that may promote insulin resistance. We
therefore examined several markers of these conditions
in Liv-DGAT1, Liv-DGAT2-low, and Liv-DGAT2-high mice.
Phosphorylation levels of Jun N-terminal kinase (JNK) and
nuclear factor kappa B (NF-kB), two inflammatory
Cell Metabolism
DGAT Liver-Transgenic Mice Lack Insulin ResistanceFigure 4. Glucose and Insulin Metabolism in Male Liv-DGAT2-Low and WT Mice on a Chow Diet
(A) Glucose tolerance tests (GTT). Glucose was administered intraperitoneally after an overnight fast, and blood glucose was measured at the
indicated times. Mice were 10–12 weeks of age; n = 12 per genotype.
(B) Insulin tolerance tests (ITT). Insulin was administered intraperitoneally after a 4 hr fast, and blood glucose was measured at the indicated times.
Mice were 10–12 weeks of age; n = 21 WT mice and 19 Liv-DGAT2-low mice.
(C–E) Hyperinsulinemic-euglycemic clamp studies. The rates of glucose infusion (C), hepatic glucose production (D), and insulin-stimulated glucose
disposal (E) were measured during constant insulin infusion at 2 mU/kg/min. Mice were 20 weeks of age; n = 7 per genotype.
(F) Increased phospho-PKB/Akt (Ser473) in livers of mice after hyperinsulinemic-euglycemic clamp studies. Control mice received injections of saline.
(G–I) Insulin signaling in Liv-DGAT2-low mice. Saline or insulin was administered intraperitoneally to chow-fed 15- to 17-week-old male mice after an
overnight fast. Livers were excised and snap frozen in liquid nitrogen after 2 min to measure PI3K activity (G) (n = 5 for each group) and after 15 min to
measure PKCl/z activity (n = 5 per group) (H) and total PKB/Akt and phospho-PKB/Akt (Ser473) (I). For (I), a representative blot is shown.markers, were increased in livers of control mice fed
a high-fat diet, but not in livers of Liv-DGAT1, Liv-
DGAT2-low, and Liv-DGAT2-high mice (Figure 6). Phos-
phorylation levels of PERK, a transmembrane kinase
implicated in the mammalian ER stress response, were
not increased in livers of Liv-DGAT2-low mice but were
increased in Liv-DGAT1 and Liv-DGAT2-high mice.
DISCUSSION
The goal of this study was to test the hypothesis that
primary hepatic steatosis causes insulin resistance. We
found that hepatic steatosis induced by overexpressing
DGAT2 in the livers of transgenic mice did not cause
insulin resistance. Similarly, hepatic steatosis induced by
overexpressing DGAT1 in the livers of transgenic mice
did not impair glucose or insulin tolerance. Thus,
although hepatic steatosis is strongly associated with
insulin resistance, hepatic lipid accumulation mediated
by DGAT overexpression is insufficient to cause insulin
resistance.
Our aim was to generate a primary increase in the TG
content of the liver by DGAT overexpression. This was
accomplished in the Liv-DGAT2-low mice, which
exhibited a 2-fold increase in DGAT2 mRNA levels and
a 5-fold increase in liver TG content, a degree of steatosisthat is physiologically relevant. Interestingly, DGAT2 over-
expression also increased the content of DG, ceramides,
and several species of long-chain fatty acyl-CoAs, all of
which are lipid metabolites that have been implicated in in-
sulin resistance (Kim et al., 2001; Neschen et al., 2005;
Schaffer, 2003; Unger, 2002). It is unclear how DGAT over-
expression increased the levels of these lipids. It may be
that the livers were simply more fat-laden due to the accu-
mulation of TG and its subsequent flux into degradation
pathways. Another possibility is that DGAT overexpres-
sion upregulated de novo lipid synthesis in general, as
suggested by the increases in the mRNAs of SREBP-1c
and its target genes. How DGAT overexpression might
induce de novo lipid synthesis is unclear, although it could
reflect a homeostatic response to increased partitioning of
fatty acids into TG.
That DGAT-mediated hepatic steatosis did not lead to
insulin resistance was clearly demonstrated in Liv-
DGAT2-low mice by their normal blood glucose and
plasma insulin levels, normal glucose and insulin toler-
ance, normal insulin sensitivity by hyperinsulinemic-
euglycemic clamp studies, and normal hepatic insulin
signaling. Because this result was surprising, we analyzed
mice expressing high levels of DGAT2 or DGAT1 in the
liver. In each instance, hepatic steatosis did not cause
glucose intolerance. Thus, hepatic steatosis mediatedCell Metabolism 6, 69–78, July 2007 ª2007 Elsevier Inc. 73
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sistance in mice.
Since hepatic steatosis and insulin resistance are often
associated, other explanations must account for the rela-
tionship. One possibility is that hepatic steatosis, when
present, is the result of insulin resistance, possibly
because the insulin signaling pathways that drive fatty
acid biosynthesis in the liver are relatively sensitive to
the high levels of insulin that accompany systemic insulin
resistance. Alternatively, the two conditions may be sepa-
rate manifestations of metabolic derangements, and
hepatic insulin resistance may reflect inflammation rather
than lipid accumulation in this tissue (Arkan et al., 2005).
Indeed, although plasma transaminase levels were mod-
estly increased in Liv-DGAT2 mice, the levels of plasma
and hepatic inflammatory markers were not increased,
Figure 5. Phenotype of Liv-DGAT1 Mice
(A) DGAT1 mRNA levels in liver and skeletal muscle of Liv-DGAT1mice
and lipogenic gene mRNA levels in liver of Liv-DGAT1 mice. Total
(mouse and human) DGAT1 mRNA and lipogenic gene levels were
measured by real-time PCR. Tissues were from 12- to 14-week-old
male mice (n = 5–6) on an ad libitum chow diet. *p < 0.05, **p <
0.001 versus WT.
(B) Hepatic levels of TG, DG, and ceramides in 12- to 15-week-old
male Liv-DGAT1 mice (n = 7–10) on an ad libitum chow diet. **p <
0.001 versus WT.
(C) Glucose tolerance tests. Glucose was administered intraperitone-
ally after an overnight fast, and blood glucose levels were measured
at the indicated times. n = 19 WT and 12 Liv-DGAT1 mice.
(D) Insulin tolerance tests. Insulin was administered intraperitoneally
after a 4 hr fast, and blood glucose was measured at the indicated
times. n = 22 WT and 15 Liv-DGAT1 mice.74 Cell Metabolism 6, 69–78, July 2007 ª2007 Elsevier Inc.consistent with a lack of inflammation. This raises the in-
teresting possibility that increased DGAT activity, by pro-
viding a sink for nonesterified lipids, is anti-inflammatory in
the liver. Of note, the livers of Liv-DGAT1 and Liv-DGAT2-
high mice exhibited apparently increased PERK phos-
phorylation, consistent with increased ER stress. How-
ever, in contrast to what has been reported for murine
obesity models (Ozcan et al., 2004), ER stress activation
in our models was not associated with insulin resistance.
Several recent studies in mice agree with our finding
that hepatic steatosis and insulin resistance may be disso-
ciated. Antisense oligonucleotide treatment targeting the
gene for DGAT2 reduces liver TG content in mice fed
a high-fat diet without improving insulin or glucose toler-
ance (Yu et al., 2005). Also, prolonged fasting (16 hr) in
mice induces hepatic steatosis without causing hepatic
insulin resistance (Heijboer et al., 2005). However, insulin
resistance is present in other rodent models of primary
hepatic steatosis. The expression of lipoprotein lipase in
the liver of transgenic mice causes hepatic steatosis and
hepatic insulin resistance as manifested by increased
hepatic glucose output (Kim et al., 2001). Also, hepatic
overexpression of mitochondrial glycerol-3-phosphate
acyltransferase in rats is associated with hepatic and
peripheral insulin resistance (Nagle et al., 2007). A
Figure 6. Inflammatory and ER Stress Markers in Liv-DGAT1
and Liv-DGAT2 Mice
Representative immunoblots of liver homogenates from 12- to 15-
week-old male mice are shown for phospho-JNK (Thr183/Tyr185)
and total JNK, phospho-NF-kB p65 (Ser536) and total NF-kB, and
phospho-PERK (Thr980). Because a specific antiserum for detecting
total PERK was unavailable, GAPDH was used as a loading control
for quantification of phospho-PERK. Liver homogenates from WT
mice fed a high-fat diet for 16 weeks served as positive controls.
Bands were quantified by densitometry (n = 4–6). *p < 0.05, **p <
0.01 versus WT.
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decarboxylase in liver of rats with diet-induced insulin
resistance, resolves hepatic steatosis and improves
whole-animal, liver, and muscle insulin sensitivities (An
et al., 2004). What accounts for the variable relationship
between hepatic steatosis and insulin resistance? One
possible explanation may be a requirement for an as yet
unidentified specific lipid or lipid-derived metabolite that
affects insulin sensitivity. Further studies involving the
direct comparison of different steatosis models and
broader profiling of lipid-derived metabolites may clarify
these issues.
Hepatic DGAT overexpression had interesting effects on
hepatic and plasma TG metabolism. The two DGAT
enzymes differed significantly in their ability to generate
steatosis in transgenic mice. Relatively small increases in
DGAT2 mRNA levels resulted in large increases in hepatic
TG content, whereas large increases in DGAT1 mRNA,
which in part reflect the low basal levels of DGAT1 expres-
sion in mouse liver (Cases et al., 1998), were not accompa-
nied by similarly marked steatosis. These results are con-
sistent with our previous finding that DGAT2 is much
more potent and specific than DGAT1 in promoting TG
synthesis (Stone et al., 2004; Yen et al., 2005) and with a re-
cent report of overexpression of DGAT enzymes in the liver
mediated by adenoviruses (Millar et al., 2006). Additionally,
both DGAT1 and DGAT2 overexpression in the liver of
transgenic mice increased hepatic TG accumulation but
did not increase (and in fact lowered) plasma TG. Because
TG secretion was similar in Liv-DGAT2 and WT mice, the
lower plasma TG levels most likely reflect alterations in
the clearance of TG from the blood. Our findings agree
with findings of short-term adenovirus-mediated overex-
pression of DGAT enzymes in the liver (Millar et al., 2006)
and support the hypothesis that factors other than TG
synthesis are rate limiting for hepatic TG secretion. How-
ever, in another study in mice, longer-term adenovirus-
mediated overexpression of DGAT1 resulted in increased
hepatic TG secretion (Yamazaki et al., 2005).
In conclusion, we show in several transgenic mouse
models that DGAT overexpression in the liver results in
lipid accumulation, including TG, DG, ceramides, and
unsaturated long-chain fatty acyl-CoAs, without associ-
ated insulin resistance. These results suggest that other
lipid mediators or related mechanisms, such as inflamma-
tion, may be required for the development of hepatic insu-
lin resistance. Importantly, our results provide insights into
the causal relationships between hepatic steatosis and
insulin resistance, conditions that are commonly associ-
ated with and increasingly prevalent in the current obesity
epidemic.
EXPERIMENTAL PROCEDURES
Generation of Transgenic Mice Overexpressing
DGAT1 or DGAT2 in the Liver
The cDNAs of human DGAT1 (1.5 kb) or DGAT2 (1.2 kb) were
ligated into the polylinker site of the plasmid LivLE6 (a gift from
J. Taylor, Gladstone Institutes), which contains promoter and enhancer
sequences of the human APOE gene that activate transcription in theliver (Simonet et al., 1993). Liv-DGAT1 and Liv-DGAT2 transgenic
constructs were microinjected into fertilized C57BL/6NHsd (Harlan
Teklad) eggs. Founder mice were bred with C57BL/6NHsd mice, and
inbred transgenic lines were established. The Liv-DGAT1 and Liv-
DGAT2 transgenes were detected by PCR of tail genomic DNA with
primers that hybridized with human and mouse DGAT1 and DGAT2
sequences (DGAT1 forward primer 50-TTGTTCAGCTCAGACAGT
GG-30, reverse primer 50-CAGCTATGGGGATCCTTCAGGAACAG-30;
DGAT2 forward primer 50-AGCTGGTGAAGACACACAACC-30, reverse
primer 50-TGATGATAGCATTGCCACTCC-30 ). The DGAT1 primers
amplify 700 and 200 bp fragments in WT and transgenic mice,
respectively; the DGAT2 primers amplify 800 and 300 bp fragments
in WT and transgenic mice, respectively. DGAT1 genotyping was con-
firmed with primers (forward primer 50-CTGCGGCGGCGGAAGAA
GAGGTG-30, reverse primer 50-CAGCTATGGGGATCCTTCAGGAA
CAG-30) that amplify the 300 bp fragment in transgenic mice. Mice
were housed in a pathogen-free barrier facility (12 hr light/12 hr dark
cycle) and fed rodent chow (Ralston Purina). Mice were studied at
10–15 weeks of age unless otherwise stated. For high-fat diet studies,
mice were fed a Western-type diet containing 21% fat and 0.2% cho-
lesterol by weight (Harlan Teklad). The high-fat diet was initiated
when mice were 10 weeks old, and mice were studied after 16 weeks
of high-fat feeding.
Real-Time Quantitative PCR
Mouse tissues were pulverized in liquid nitrogen, and total RNA was
isolated with RNA Stat-60 (Tel-Test) according to the manufacturer’s
protocol. RNA (5 mg) was reverse transcribed with SuperScript III
reverse transcriptase and oligo(dT) primers (Invitrogen) to generate
cDNA. Real-time quantitative PCR was performed with a PerkinElmer
ABI Prism 7700 (Applied Biosystems) and SYBR green detection of
amplified products. Each 25 ml PCR reaction mix contained 2 ml of
cDNA, 12.5 ml of 23 SYBR green master mix (QIAGEN), and 10 pmol
of each primer. Relative mRNA abundance was normalized to the
internal standard cyclophilin. Primers for different genes are listed in
Table S1. The primers used for DGAT1 and DGAT2 are located in
regions where the human and mouse DGAT1 and DGAT2 cDNA
sequences are 100% identical and therefore detect both mRNAs.
Immunoblots
For DGAT2, liver tissue was homogenized in buffer A (50 mM Tris-HCl
[pH 7.4], 250 mM sucrose) containing proteinase inhibitors (Roche
Diagnostics). Samples (100 mg protein) were subjected to SDS-
PAGE, transferred to polyvinylidene fluoride membranes, and incu-
bated with an anti-DGAT2 polyclonal antibody (1:2000) that recognizes
the carboxyl terminus of DGAT2 or with an anti-GAPDH monoclonal
antibody (1:2000) (Covance Research Products).
For JNK and NF-kB, livers were homogenized in 20 mM
HEPES,1 mM DTT, 1 mM Na4P2O7, 2 mM EDTA, 1% Triton X-100,
10% glycerol (v/v), 3 mM benzamidine, 1 mM phenylmethylsulfonyl
fluoride, 5 ml/ml phosphatase inhibitor cocktail 2 (Sigma), and 5 ml/ml
protease inhibitor cocktail (Sigma). Samples (60 mg protein) were sub-
jected to SDS-PAGE, transferred to polyvinylidene fluoride mem-
branes, and incubated with an anti-phospho-JNK (Thr183/Tyr185)
antibody (1:1000); anti-JNK antibody (1:1000), which recognizes
both 46 and 54 kDa JNK isoforms; anti-phospho-NF-kB p65
(Ser536) antibody (1:1000); or anti-NF-kB p65 antibody (1:1000) (Cell
Signaling Technology).
For phospho-PERK (Thr980), livers were homogenized in buffer
containing 25 mM Tris-HCl (pH 7.4), 10 mM Na3VO4, 100 mM NaF,
50 mM Na4P2O7, 10 mM EGTA, 10 mM EDTA, 1% NP-40, and protein-
ase inhibitors (Roche Diagnostics). Samples (30 mg protein) were
subjected to SDS-PAGE, transferred to polyvinylidene fluoride mem-
branes, and incubated with an anti-phospho-PERK (Thr980) polyclonal
antibody (1:1000) (Cell Signaling Technology). In all immunoblots,
antibody binding was detected with appropriate secondary antibodies
and chemiluminescence (Pierce Biotechnology).Cell Metabolism 6, 69–78, July 2007 ª2007 Elsevier Inc. 75
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Liver and skeletal muscle (gastrocnemius and quadriceps) were pul-
verized in liquid nitrogen and homogenized in buffer A containing
proteinase inhibitors. Lipids were extracted in chloroform:methanol
(2:1) and separated by thin-layer chromatography (TLC) on silica gel
G-60 TLC plates with the solvent system hexane:ethyl ether:acetic
acid (80:20:1). TG was visualized by exposure to iodine, and bands
were scraped and analyzed as described (Snyder and Stephens,
1959) with triolein as a standard (Sigma-Aldrich).
DG and ceramides were analyzed as described (Preiss et al., 1986).
Liver and skeletal muscle were freeze dried and dissected free of
visible connective tissue. Lipids were extracted with chloroform:
methanol:PBS/0.2% SDS (1:2:0.8). DG kinase (Sigma-Aldrich) and g-
[32P]ATP (15 mCi/mmol cold ATP) were added to lysates preincubated
with cardiolipin/octylglucoside. The reaction was stopped after 2 hr by
the addition of chloroform:methanol (2:1), and extracted lipids were
spotted onto TLC plates and developed in chloroform:acetate:
methanol:acetic acid:water (100:40:30:20:10). [32P]phosphatidic acid
(corresponding to DG content) and ceramide-1-phosphate (corre-
sponding to ceramide content) were identified and scraped from the
TLC plate for scintillation counting (Tri-Carb 2500TR, Packard).
Liver acyl-CoA esters were analyzed by a method based on that of
Magnes et al. (2005), which relies on an extraction procedure
described by Deutsch et al. (1994). The CoAs were further purified
by solid-phase extraction using Oasis HLB (1 cm3, 30 mg) cartridges
(Waters). The esters were eluted with 0.55 ml of acetonitrile:water
(35:65) containing 15 mM ammonium hydroxide. The acyl-CoAs
were analyzed by flow injection analysis using positive electrospray
ionization on a Quattro micro triple quadrupole mass spectrometer
(Waters) employing acetonitrile:water (60:40) containing 30 mM
ammonium hydroxide as the mobile phase. Spectra were acquired in
the multichannel acquisition mode by monitoring the neutral loss of 507
amu (phosphoadenosine diphosphate) and scanning from m/z 890–
1060. Heptadecanoyl-CoA was employed as an internal standard,
and the endogenous CoAs were quantified using calibrators prepared
by spiking liver homogenates with authentic CoAs (Sigma) containing
saturated acyl chain lengths C8–C18 and unsaturated species of
C16:1, C18:2, C18:1, and C20:4. Corrections for the heavy isotope
effects, mainly 13C, to the adjacent m+2 spectral peaks in a particular
chain-length cluster were made empirically by referring to the
observed spectra for the analytical standards.
Blood Analyses
Mice were fasted overnight (16 hr) for lipid analyses and 6 hr for insulin
and b-hydroxybutyrate determinations. Blood was obtained from tail
veins of unanesthetized mice. Kits were used to measure plasma
FFA (Wako Pure Chemical Industries), TG (Roche Diagnostics), and
b-hydroxybutyrate levels (Stanbio). Plasma insulin levels were mea-
sured with an ELISA kit (Linco Research). Blood glucose was mea-
sured with a glucometer (OneTouch Ultra, LifeScan). Inflammatory
markers (monocyte chemoattractant protein 1 and tissue plasminogen
activator inhibitor 1) and adipokines (adiponectin, leptin, and resistin)
were measured by Novartis using Luminex xMAP technology (Linco
Research), and transaminases (alanine transaminase and aspartate
aminotransferase) were measured using an AU400e Chemistry Im-
muno Analyzer (Olympus America) in mice fasted for 24 hr and then
refed for 12 hr.
Body Composition
Mice were fasted for 4 hr and anesthetized with isoflurane, and body
composition was analyzed by dual energy X-ray absorptiometry with
a PIXImus2 scanner (GE Healthcare Lunar).
Glucose and Insulin Tolerance Tests
For glucose tolerance tests, mice were fasted overnight, and glucose
(1 g/kg body weight) was administered intraperitoneally. For insulin tol-
erance tests, mice were fasted for 4 hr, and bovine insulin (1 unit/kg
body weight, Sigma-Aldrich) was administered intraperitoneally.76 Cell Metabolism 6, 69–78, July 2007 ª2007 Elsevier Inc.Hyperinsulinemic-Euglycemic Clamp Studies
Two cannulae (Micro-Renathane MRE 025, 0.025 inch outer diameter,
0.012 inch inner diameter; Braintree Scientific) were surgically
implanted into the right jugular vein of 20-week-old male mice (n =
7 per genotype) as described (Hevener et al., 2003). Cannulae were
secured in the vessel, tunneled subcutaneously, and brought to the
exterior at the back of the neck. Skin incisions were closed with
sutures, and each mouse was given 1 ml of saline subcutaneously to
prevent dehydration and placed in an isothermic environment for
24 hr. Three days after surgery, glucose turnover was measured in
the basal state and during hyperinsulinemia to quantify whole-body
insulin sensitivity. Mice were fasted for 6 hr and then placed in
a restrainer to which they had been acclimated. One cannula was
connected to an infusion syringe containing D-[3-3H]glucose (New
England Nuclear). Glucose was infused (0.084 mCi/min) for 90 min
(2 ml/min), and two blood samples (15 ml each) were taken 90 min after
tracer equilibration to determine basal glucose turnover rate. After
basal sampling, the syringe was changed to one containing [3H]glu-
cose and human insulin (2 mU/kg/min, Novolin R; Novo Nordisk Phar-
maceutical Industries). Simultaneously, the second cannula was con-
nected to a syringe containing a 50% dextrose solution (Abbott
Laboratories) infused at a variable rate. Blood (5 ml) was sampled at
10 min intervals for the determination of blood glucose, and the dex-
trose infusion rate was adjusted to maintain the blood glucose concen-
tration at 130 mg/dl. A steady state (stable blood glucose concentra-
tion and exogenous glucose infusion rate) was achieved within
90 min. Blood was sampled at 100 and 120 min for the determination
of tracer specific activity. The insulin-stimulated glucose disposal and
hepatic glucose production rates were determined using the Steele
equation (Hevener et al., 2003).
Insulin Signaling
After an overnight fast, PBS or insulin (1 U/kg body weight) was admin-
istered intraperitoneally to mice. After 2 min (for PI3K activity assay) or
15 min (for PKB/Akt phosphorylation and PKCl/z activity assay), livers
were excised and snap frozen in liquid nitrogen. For PI3K activity as-
say, tissue lysates were immunoprecipitated overnight at 0C–4C
with anti-IRS1 antibodies (Upstate) and assayed for PI3K enzyme
activity as described (Kanoh et al., 2000).
For analysis of insulin-stimulated PKB/Akt phosphorylation, tissue
was pulverized in liquid nitrogen and homogenized in buffer A contain-
ing proteinase inhibitors. The homogenates were centrifuged at 8003
g for 5 min, and the supernatant protein (50 mg) was analyzed by SDS-
PAGE and immunoblotting with antibodies that detect phospho-Akt
(Ser473) and total Akt (Cell Signaling Technology).
PKCl/z activity assay was performed as described (Chen et al.,
2002; Kanoh et al., 2003; Standaert et al., 1997). Briefly, tissue lysates
were immunoprecipitated with polyclonal antibodies that recognize
specific isoforms of PKC (Santa Cruz Biotechnology). Precipitates
were then incubated for 8 min with [g-32P]ATP and the serine analog
of PKC3 pseudosubstrate (BioSource International). Aliquots of the
mixtures were spotted on p81 filter paper, and 32P radioactivity was
measured.
Mouse Peritoneal Macrophages
Mouse peritoneal macrophages were obtained by peritoneal lavage
3 days after intraperitoneal injection of thioglycolate. Cells were dis-
persed in 100 mm dishes with DMEM containing 10% fetal calf
serum (FCS). After 2 hr, cells were washed with PBS to remove unat-
tached cells and then cultured in DMEM with 10% FCS for 24 hr before
harvesting for RNA extraction.
Statistical Analyses
Data are presented as the mean ± SEM. Measurements were com-
pared via two-tailed t test or Mann-Whitney rank-sum test. Glucose
and insulin tolerance tests were compared with repeated-measures
ANOVA and Bonferroni post hoc analysis. The area under the curve
was calculated using the trapezoid rule (GraphPad Prism 4 software).
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Supplemental Data include one figure and one table and can be found
with this article online at http://www.cellmetabolism.org/cgi/content/
full/6/1/69/DC1/.
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